Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,341.31
(
0.00%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 132304

Friday, 12/02/2011 2:30:58 PM

Friday, December 02, 2011 2:30:58 PM

Post# of 257300

Insurers may have something else in mind.

Third-party payers will be more than happy to pay for a short course of treatment that increases the likelihood of attaining an SVR and thereby eliminating future costs of the disease entirely. This will be one of the easiest treatment decisions the payers will ever have to make, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today